Pancreatitis potentially associated drugs as a risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis : a prospective cohort study
OBJECTIVES: The aim of this study was to assess the role of known risk factors and specifically evaluate the role of pancreatitis potentially associated drugs as potential risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP).
METHODS: This was a prospective, single-center cohort study conducted in a tertiary university hospital. All eligible ERCP procedures within a 16-month period were evaluated, and all interventions, patient characteristics, and medications used were documented. The association of potential risk factor with PEP was investigated with univariable analyses. Those statistically significant were entered in a multivariable regression model.
RESULTS: Three hundred eighteen ERCP procedures were studied. Post-ERCP pancreatitis occurred in 28 patients (8.8%). Twenty-three potential risk factors were studied in univariable analyses, and 3 of them were found to be nominally statistically significant. These 3 factors were independently associated with PEP in the multivariable model and included the use of pancreatitis potentially associated drugs, belonging to Badalov classes I or II, during the last month before ERCP (odds ratio [OR], 4.39; 95% confidence interval [CI], 1.70-5.47; P = 0.003), more than 1 guide-wire insertions in the pancreatic duct (OR, 5.00; 95% CI, 1.97-12.81; P = 0.001) and bile duct stone extraction (OR, 0.12; CI, 0.05-0.32; P < 0.001).
CONCLUSIONS: Pancreatitis potentially associated drugs used before ERCP seem to increase the risk for PEP.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Pancreas - 42(2013), 4 vom: 15. Mai, Seite 601-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sigounas, Dimitrios E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.12.2013 Date Revised 21.03.2022 published: Print ErratumIn: Pancreas. 2014 Aug;43(6):978-9 Citation Status MEDLINE |
|---|
| doi: |
10.1097/MPA.0b013e31827309fd |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM226321304 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226321304 | ||
| 003 | DE-627 | ||
| 005 | 20231224071155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MPA.0b013e31827309fd |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0754.xml |
| 035 | |a (DE-627)NLM226321304 | ||
| 035 | |a (NLM)23548878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sigounas, Dimitrios E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pancreatitis potentially associated drugs as a risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis |b a prospective cohort study |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.12.2013 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Pancreas. 2014 Aug;43(6):978-9 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The aim of this study was to assess the role of known risk factors and specifically evaluate the role of pancreatitis potentially associated drugs as potential risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) | ||
| 520 | |a METHODS: This was a prospective, single-center cohort study conducted in a tertiary university hospital. All eligible ERCP procedures within a 16-month period were evaluated, and all interventions, patient characteristics, and medications used were documented. The association of potential risk factor with PEP was investigated with univariable analyses. Those statistically significant were entered in a multivariable regression model | ||
| 520 | |a RESULTS: Three hundred eighteen ERCP procedures were studied. Post-ERCP pancreatitis occurred in 28 patients (8.8%). Twenty-three potential risk factors were studied in univariable analyses, and 3 of them were found to be nominally statistically significant. These 3 factors were independently associated with PEP in the multivariable model and included the use of pancreatitis potentially associated drugs, belonging to Badalov classes I or II, during the last month before ERCP (odds ratio [OR], 4.39; 95% confidence interval [CI], 1.70-5.47; P = 0.003), more than 1 guide-wire insertions in the pancreatic duct (OR, 5.00; 95% CI, 1.97-12.81; P = 0.001) and bile duct stone extraction (OR, 0.12; CI, 0.05-0.32; P < 0.001) | ||
| 520 | |a CONCLUSIONS: Pancreatitis potentially associated drugs used before ERCP seem to increase the risk for PEP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Christodoulou, Dimitrios K |e verfasserin |4 aut | |
| 700 | 1 | |a Tatsioni, Athina |e verfasserin |4 aut | |
| 700 | 1 | |a Katsanos, Konstantinos H |e verfasserin |4 aut | |
| 700 | 1 | |a Baltayiannis, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Kappas, Aggelos |e verfasserin |4 aut | |
| 700 | 1 | |a Ioannidis, John P A |e verfasserin |4 aut | |
| 700 | 1 | |a Tsianos, Epameinondas V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pancreas |d 1988 |g 42(2013), 4 vom: 15. Mai, Seite 601-6 |w (DE-627)NLM012605158 |x 1536-4828 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2013 |g number:4 |g day:15 |g month:05 |g pages:601-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MPA.0b013e31827309fd |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2013 |e 4 |b 15 |c 05 |h 601-6 | ||